Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
01 nov. 2021 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
30 sept. 2021 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
26 juil. 2021 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
12 mai 2021 07h30 HE
|
Minerva Neurosciences, Inc
Top-line results from the open-label extension of phase 3 monotherapy trial of roluperidone for the treatment of negative symptoms of schizophrenia show continuous improvement in negative symptoms,...
Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension
11 mai 2021 16h15 HE
|
Minerva Neurosciences, Inc
Key results Continuous improvement in negative symptoms as measured by Positive and Negative Syndrome Scale (PANSS) Marder Negative Symptom Factor Score (NSFS) observed over one year (12-week...
Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates
08 mars 2021 07h30 HE
|
Minerva Neurosciences, Inc
Phase 3 open-label extension completed on schedule in patients with negative symptoms of schizophrenia and data will be available in H1 2021 Minerva’s royalty interest in seltorexant acquired by...
ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NERV
08 janv. 2021 17h08 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017...
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
01 déc. 2020 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
03 août 2020 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
29 mai 2020 09h20 HE
|
Minerva Neurosciences, Inc
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259,...